We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Assays Evaluated for Influenza in Blood Donors

By LabMedica International staff writers
Posted on 26 Mar 2012
Sensitive molecular assays have been used to screen blood donors for the presence of influenza viremia via ribonucleic acid (RNA) testing.

Several influenza RNA amplification assays, including transcription-mediated amplification (TMA) and two reverse-transcription polymerase chain reaction (RT-PCR) assays were evaluated and used to test donor samples. More...


Scientists at the Blood Systems Research Institute (San Francisco, CA, USA) collaborating with other institutes, retrospectively tested samples from 478 subjects drawn at sites with high influenza activity. They collected prospective samples from 1,004 blood donors who called their donation center within three days of donation complaining of influenza-like illness (ILI). The plasma collected on the day of donation for these subjects was tested.

A number of different influenza RNA detection assays were evaluated prior to testing donor samples, all of which were previously shown to detect commonly circulating contemporary influenza viruses. The MGB Alert system (Epoch Biosciences; Bothell, WA, USA) uses RNA extraction followed by RT-PCR. The Prodesse ProFlu-1 assay (Gen-Probe, San Diego, CA, USA) uses RNA extraction followed by a TaqMan-based, real-time RT-PCR amplification targeting the influenza A matrix gene. Transcription-mediated amplification, also from Gen-Probe, uses a target-capture probe for influenza A matrix gene during RNA extraction followed by isothermal amplification using bacteriophage T7 RNA polymerase and Moloney murine leukemia virus reverse transcriptase. The assays were validated on spiked samples and an animal model.

Of the repository samples, two of 478 plasma samples were initially reactive, but were not repeat reactive by influenza TMA. Of blood donors reporting ILI symptoms after donation, only one of 1,004 samples was TMA initially reactive, but was not repeat reactive, while all samples were nonreactive by RT-PCR testing. The authors reported that they failed to detect influenza A viremia using very sensitive tests in blood samples from donors collected during periods of high influenza transmission in the community, with the majority of the tested donors reporting symptoms of influenza-like illness. The preponderance of evidence from this and other studies thus suggests that influenza viremia is at most an exceedingly rare event in blood donors, who are healthy at the time of donation, and that influenza viremia only occurs in subjects with moderate to severe disease. The study was published on March 15, 2012, in the Journal of Infectious Diseases.

Related Links:

Blood Systems Research Institute
Epoch Biosciences
Gen-Probe



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.